Detecting Muscle Invasion of Bladder Cancer Using a Proposed Magnetic Resonance Imaging Strategy.
Vesical Imaging-Reporting and Data System
muscle-invasive bladder cancer
nonmuscle-invasive bladder cancer
tumor contact length
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
16
04
2021
received:
10
02
2021
accepted:
19
04
2021
pubmed:
18
5
2021
medline:
30
9
2021
entrez:
17
5
2021
Statut:
ppublish
Résumé
Accurate evaluation of the invasion depth of tumors with a Vesical Imaging-Reporting and Data System (VI-RADS) score of 3 is difficult. To evaluate the diagnostic performance of a new magnetic resonance imaging (MRI) strategy based on the integration of the VI-RADS and tumor contact length (TCL) for the diagnosis of muscle-invasive bladder cancer (MIBC). Single center, retrospective. A group of 179 patients with a mean age of 67 years (range, 24.0-96.0) underwent multiparametric MRI (mpMRI) before surgery, including 147 (82.1%) males and 32 (17.9%) females. Twenty-four (13.4%), 90 (50.3%), 43 (24.0%), 15 (8.4%), and 7 (3.9%) cases were Ta, T1, T2, T3, and T4, respectively. A 1.5 T and 3.0 T, T2-weighted turbo spin-echo (TSE), single-shot echo-planar (SS-EPI), diffusion-weighted imaging (DWI), and T1-weighted volumetric interpolated breath-hold examination (T1-VIBE). Three radiologists independently graded the VI-RADS score and measured the TCL on index lesion images. A proposed MRI strategy called VI-RADS_TCL was introduced by modifying the VI-RADS score, which was downgraded to VI-RADS 3F (equal to a VI-RADS score of 2) if VI-RADS = 3 and TCL < 3 cm. Intraclass correlation coefficients (ICCs), Mann-Whitney U test, chi-square tests, receiver operating characteristic (ROC) curves, and 2 × 2 contingency tables were applied. Inter-reader agreement values were 0.941 (95% CI, 0.924-0.955) and 0.934 (95% CI, 0.916-0.948) for the TCL and VI-RADS score. The TCL was significantly increased in the MIBC group (6.40-6.85 cm) compared with the NMIBC group (1.98-2.45 cm) (P < 0.05). The specificity and positive predictive values (PPV) of VI-RADS_TCL were 82.46%-87.72% and 90.91%-91.59%, which were significantly greater than VI-RADS score (P < 0.05). Additionally, 52.17%-55.88% NMIBC lesions with VI-RADS 3 were downgraded to 3F by using VI-RADS_TCL. The proposed MRI strategy could reduce the false-positive rate of lesions with a VI-RADS score of 3 while retaining sensitivity. 4 TECHNICAL EFFICACY: 2.
Sections du résumé
BACKGROUND
Accurate evaluation of the invasion depth of tumors with a Vesical Imaging-Reporting and Data System (VI-RADS) score of 3 is difficult.
PURPOSE
To evaluate the diagnostic performance of a new magnetic resonance imaging (MRI) strategy based on the integration of the VI-RADS and tumor contact length (TCL) for the diagnosis of muscle-invasive bladder cancer (MIBC).
STUDY TYPE
Single center, retrospective.
SUBJECTS
A group of 179 patients with a mean age of 67 years (range, 24.0-96.0) underwent multiparametric MRI (mpMRI) before surgery, including 147 (82.1%) males and 32 (17.9%) females. Twenty-four (13.4%), 90 (50.3%), 43 (24.0%), 15 (8.4%), and 7 (3.9%) cases were Ta, T1, T2, T3, and T4, respectively.
FIELD STRENGTH/SEQUENCE
A 1.5 T and 3.0 T, T2-weighted turbo spin-echo (TSE), single-shot echo-planar (SS-EPI), diffusion-weighted imaging (DWI), and T1-weighted volumetric interpolated breath-hold examination (T1-VIBE).
ASSESSMENT
Three radiologists independently graded the VI-RADS score and measured the TCL on index lesion images. A proposed MRI strategy called VI-RADS_TCL was introduced by modifying the VI-RADS score, which was downgraded to VI-RADS 3F (equal to a VI-RADS score of 2) if VI-RADS = 3 and TCL < 3 cm.
STATISTICAL TESTS
Intraclass correlation coefficients (ICCs), Mann-Whitney U test, chi-square tests, receiver operating characteristic (ROC) curves, and 2 × 2 contingency tables were applied.
RESULTS
Inter-reader agreement values were 0.941 (95% CI, 0.924-0.955) and 0.934 (95% CI, 0.916-0.948) for the TCL and VI-RADS score. The TCL was significantly increased in the MIBC group (6.40-6.85 cm) compared with the NMIBC group (1.98-2.45 cm) (P < 0.05). The specificity and positive predictive values (PPV) of VI-RADS_TCL were 82.46%-87.72% and 90.91%-91.59%, which were significantly greater than VI-RADS score (P < 0.05). Additionally, 52.17%-55.88% NMIBC lesions with VI-RADS 3 were downgraded to 3F by using VI-RADS_TCL.
DATA CONCLUSION
The proposed MRI strategy could reduce the false-positive rate of lesions with a VI-RADS score of 3 while retaining sensitivity.
EVIDENCE LEVEL
4 TECHNICAL EFFICACY: 2.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1212-1221Informations de copyright
© 2021 International Society for Magnetic Resonance in Medicine.
Références
Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71(1):7-33.
Svatek R, Hollenbeck B, Holmäng S, et al. The economics of bladder cancer: Costs and considerations of caring for this disease. Eur Urol 2014;66(2):253-262.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 2017;71(1):96-108.
Leow J, Cole A, Seisen T, et al. Variations in the costs of radical cystectomy for bladder cancer in the USA. Eur Urol 2018;73(3):374-382.
Babjuk M, Burger M, Compérat E, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol 2019;76(5):639-657.
Sherif A, Jonsson M, Wiklund N. Treatment of muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2007;7(9):1279-1283.
Witjes J, Compérat E, Cowan N, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 2014;65(4):778-792.
Josephson D, Pasin E, Stein J. Superficial bladder cancer: Part 2. Management. Expert Rev Anticancer Ther 2007;7(4):567-581.
Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: Evaluation of staging accuracy. AJR Am J Roentgenol 2005;184(1):121-127.
Barentsz J, Jager G, Mugler J, et al. Staging urinary bladder cancer: Value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences. AJR Am J Roentgenol 1995;164(1):109-115.
Panebianco V, De Berardinis E, Barchetti G, et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 2017;27(9):3759-3766.
Panebianco V, Barchetti F, de Haas R, et al. Improving staging in bladder cancer: The increasing role of multiparametric magnetic resonance imaging. Eur Urol Focus 2016;2(2):113-121.
Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y. The diagnostic value of MR imaging in differentiating T staging of bladder cancer: A meta-analysis. Radiology 2018;286(2):502-511.
Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: Development of VI-RADS (vesical imaging-reporting and data system). Eur Urol 2018;74(3):294-306.
Wang H, Luo C, Zhang F, et al. Multiparametric MRI for bladder cancer: Validation of VI-RADS for the detection of detrusor muscle invasion. Radiology 2019;291(3):668-674.
Barchetti G, Simone G, Ceravolo I, et al. Multiparametric MRI of the bladder: Inter-observer agreement and accuracy with the vesical imaging-reporting and data system (VI-RADS) at a single reference center. Eur Radiol 2019;29(10):5498-5506.
Kim S. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol (New York) 2020;45(2):491-498.
Ueno Y, Takeuchi M, Tamada T, et al. Diagnostic accuracy and interobserver agreement for the vesical imaging-reporting and data system for muscle-invasive bladder cancer: A multireader validation study. Eur Urol 2019;76(1):54-56.
Del Giudice F, Barchetti G, De Berardinis E, et al. Prospective assessment of vesical imaging reporting and data system (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection. Eur Urol 2020;77(1):101-109.
Ueno Y, Tamada T, Takeuchi M, et al. Vesicle imaging and data reporting system (VI-RADS): Multi-institutional multi-reader diagnostic accuracy and inter-observer agreement study. AJR Am J Roentgenol 2021;216(5):1257-1266.
Kim W, Kim C, Park J, Kim M, Kim J. Evaluation of extracapsular extension in prostate cancer using qualitative and quantitative multiparametric MRI. J Magn Reson Imag 2017;45(6):1760-1770.
Green R, Epstein E. Dynamic contrast-enhanced ultrasound improves diagnostic performance in endometrial cancer staging. Ultrasound Obstet Gynecol 2020;56(1):96-105.
Nougaret S, Reinhold C, Alsharif S, et al. Endometrial cancer: Combined MR volumetry and diffusion-weighted imaging for assessment of myometrial and lymphovascular invasion and tumor grade. Radiology 2015;276(3):797-808.
Liu Y, Liu H, Qian C, Lin M, Li F. Utility of quantitative contrast-enhanced ultrasound for the prediction of extracapsular extension in papillary thyroid carcinoma. Sci Rep 2017;7(1):1472.
Rosenkrantz A, Shanbhogue A, Wang A, Kong M, Babb J, Taneja S. Length of capsular contact for diagnosing extraprostatic extension on prostate MRI: Assessment at an optimal threshold. J Magn Reson Imag 2016;43(4):990-997.
Feng S, Yang S. The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagn Interven Radiol (Ankara, Turkey) 2019;25(4):270-279.
Ahn H, Hwang S, Lee H, et al. Quantitation of bladder cancer for the prediction of muscle layer invasion as a complement to the vesical imaging-reporting and data system. Eur Radiol 2021;31(3):1656-1666.
Zachos I, Tzortzis V, Mitrakas L, et al. Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG. Tumour Biol 2014;35(5):4185-4189.
Rodríguez Faba O, Palou J. Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer. Curr Opin Urol 2012;22(5):415-420.
Liu S, Xu F, Xu T, Yan Y, Yao X, Tang G. Evaluation of vesical imaging-reporting and data system (VI-RADS) scoring system in predicting muscle invasion of bladder cancer. Transl Androl Urol 2020;9(2):445-451.
Wang H, Pui M, Guo Y, et al. Multiparametric 3-T MRI for differentiating low-versus high-grade and category T1 versus T2 bladder urothelial carcinoma. AJR Am J Roentgenol 2015;204(2):330-334.
Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: Diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009;251(1):112-121.
Vikram R, Sandler C, Ng C. Imaging and staging of transitional cell carcinoma: Part 1, lower urinary tract. AJR Am J Roentgenol 2009;192(6):1481-1487.
Lee C, Tan C, Faria S, Kundra V. Role of imaging in the local staging of urothelial carcinoma of the bladder. AJR Am J Roentgenol 2017;208(6):1193-1205.
Kulkarni G, Hakenberg O, Gschwend J, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57(1):60-70.
Gordon P, Thomas F, Noon A, Rosario D, Catto J. Long-term outcomes from re-resection for high-risk non-muscle-invasive bladder cancer: A potential to rationalize use. Eur Urol Focus 2019;5(4):650-657.
Ark J, Keegan K, Barocas D, et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int 2014;113(6):894-899.